Literature DB >> 17000396

Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.

Giovanni D Aletti1, Karl C Podratz, Monica B Jones, William A Cliby.   

Abstract

BACKGROUND: The peritoneum of the cul-de-sac is frequently affected in advanced ovarian cancer patients. Stripping of the pelvic peritoneum (SoP) combined with rectosigmoidectomy (RS) in patients with confluent tumor are safe techniques that can eradicate macroscopic disease. We evaluated the therapeutic value of this maximal surgical effort in advanced ovarian cancer. STUDY
DESIGN: Data from all consecutive patients with stages IIIC and IV epithelial ovarian cancer, primarily operated on from 1994 through 1998, were collected and analyzed using the chi-square test, Cox regression analysis, and Kaplan-Meier curves including log-rank test.
RESULTS: Two hundred forty-four eligible patients were identified; 209 patients had tumor involving the peritoneum of the cul-de-sac. For this subgroup, those who were managed with stripping of the peritoneum (SoP, n=77) or rectosigmoidectomy (RS, N=57) had improved 5-year overall survivals relative to those who were not (n=75). (SoP=37% versus RS=39% versus neither=6%; p < 0.0001). In the subgroup of patients with cul-de-sac involvement optimally cytoreduced, we noted a survival benefit for those who were managed with a maximal pelvic surgical effort (5-year overall survival, 38% [SoP] versus 38% [RS] versus 15% [neither]; p=0.02). When evaluating patients with no macroscopic residual disease, a survival advantage for patients managed with RS compared with SoP was observed (5-year overall survival, 89% (RS) versus 50% (RS); p=0.04).
CONCLUSIONS: Surgical resection of cul-de-sac disease by SoP and RS is associated with improved survival in ovarian cancer patients. Tumor resection with en bloc RS may be preferable to allowing microscopic or infiltrative residual tumor.

Entities:  

Mesh:

Year:  2006        PMID: 17000396     DOI: 10.1016/j.jamcollsurg.2006.06.027

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  18 in total

1.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

Review 2.  Radical surgery in ovarian cancer.

Authors:  Deepa Maheswari Narasimhulu; Fady Khoury-Collado; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

3.  Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer.

Authors:  Kana Tanaka; Yoshifumi Shimada; Koji Nishino; Kosuke Yoshihara; Masato Nakano; Hitoshi Kameyama; Takayuki Enomoto; Toshifumi Wakai
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

4.  Surgical technique of visceral segmental serosectomy for advanced ovarian cancer.

Authors:  Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

Review 5.  Extrapelvic bowel resection and anastomosis in cytoreductive surgery for ovarian cancer.

Authors:  Joo-Hyuk Son; Suk-Joon Chang
Journal:  Gland Surg       Date:  2021-03

6.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.

Authors:  Sean C Dowdy; Ralitsa T Loewen; Giovanni Aletti; Simone S Feitoza; William Cliby
Journal:  Gynecol Oncol       Date:  2008-04-01       Impact factor: 5.482

7.  Rectosigmoidian Involvement in Advanced-stage Ovarian Cancer - Intraoperative Decisions.

Authors:  Nicolae Bacalbasa; Irina Balescu; Simona Dima
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 8.  Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Authors:  Maria Luisa Gasparri; Giovanni Grandi; Daniele Bolla; Beat Gloor; Sara Imboden; Pierluigi Benedetti Panici; Michael D Mueller; Andrea Papadia
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

9.  Clinical Impact of a Surgical Energy Device in Advanced Ovarian Cancer Surgery Including Bowel Resection.

Authors:  Giuseppe Vizzielli; Carmine Conte; Massimo Romano; Anna Fagotti; Barbara Costantini; Claudio Lodoli; Salvatore Gueli Alletti; Khaled Gaballah; Fabio Pacelli; Alfredo Ercoli; Giovanni Scambia; Valerio Gallotta
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

10.  Clinical Phenotypes of Tumors Invading the Rectosigmoid Colon Affecting the Extent of Debulking Surgery and Survival in Advanced Ovarian Cancer.

Authors:  Soo Jin Park; Jaehee Mun; Eun Ji Lee; Sunwoo Park; Sang Youn Kim; Whasun Lim; Gwonhwa Song; Jae-Weon Kim; Seungmee Lee; Hee Seung Kim
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.